Igg4-related Disease
📧 Sign up to get email alerts when something new happens for Igg4-related Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2017-11-17Clinical Trial Update: Retrospective Study for Diagnosis of Undetected IgG4 Related Diseases in Patients With High Serum IgG4 Levels.
A retrospective clinical trial update examining methods for diagnosing undetected IgG4-related diseases in patients with high serum IgG4 lev…
-
CLINICAL_TRIALS research · 2017-11-09Clinical Trial Update: A Laboratory Scan of Patients With Aortic Aneurysms to IgG4 Levels in the Blood [NA]
A clinical trial update examining IgG4 levels in the blood of patients with aortic aneurysm to explore potential links to IgG4-related disea…
-
CLINICAL_TRIALS research · 2017-04-11Clinical Trial Update: A Prospective Cohort Study of IgG4RD in China
Prospective cohort study investigating IgG4-related disease conducted in China; currently recruiting.
-
CLINICAL_TRIALS research · 2017-04-07Clinical Trial Update: 18F-FDG PET/CT for IgG4-Related Disease [EARLY_Phase 1]
An early-phase 1 clinical trial evaluating 18F-FDG PET/CT imaging for IgG4-related disease, sponsored by Peking Union Medical College Hospit…
-
CLINICAL_TRIALS research · 2017-01-24Clinical Trial Update: National Registry of IgG4-RD in China
Recruitment is ongoing for China's National Registry of IgG4-related disease, sponsored by Peking Union Medical College Hospital.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2017-01-24Clinical Trial Update: Study of Treatment Response on IgG4 Related Disease (IgG4RD) [Phase 2]
This document provides an update on a Phase 2 clinical trial evaluating treatment response in IgG4-related disease.
-
CLINICAL_TRIALS research · 2013-01-01Clinical Trial Update: Glucocorticoids in Patients With IgG4-RD [Phase 2, Phase 3]
This entry provides an update on a Phase 2/Phase 3 trial evaluating glucocorticoids for IgG4-related disease. The current status is UNKNOWN.